
## Photoactivatable metal compounds




### Photoactivatable metal compounds

These complexes are inert and non-toxic to cells in the dark.

Upon irradiation at the tumor site, they undergo various photochemical reactions, including isomerization, substitution, and reduction.


The photoactivation pathway of metal complexes does not rely on  $O_2$ , which is a significant advantage over the photosensitizers used in current PDT. However, photoactivation – contrary to PDT – is a stoichiometric proces.



Activation of the metal center


Selective release of active ligands (photo-uncaging)

# Caged compounds and photo-uncaging




Photolabile protecting groups, attached to a defined position of a molecule, can be used to gain spatio-temporal control over the concentration of the active form of a molecule.


### Photoactivatable Ru compounds




Phototoxicity Index, PI

### Photoactivatable Ru compounds





#### Metal compounds for the delivery of active molecules






NO, CO, 4-aminopyridine (4-AP, K+ channel blocker), γ-aminobutyric acid (GABA, a neurotransmitter),...

## Caged compounds and photo-uncaging


NO Releasing Molecules = NORM CO Releasing Molecules = CORM

Photo-NORM Photo-CORM



#### Photo-release of neurotransmitters

GABA = γ-aminobutyric acid: inhibitory neurotransmitter Glutamic acid: excitatory neurotransmitter 4-AP = 4-aminopyridine: K+ channel blocker



Type II PDT

Type I PDT